Baseline Assessment for Anti-Tubercular Treatment

Starting anti-tubercular treatment requires a baseline assessment to monitor for potential adverse effects. Many anti-tubercular drugs, such as isoniazid and rifampicin, are known to potentially cause liver injury (hepatotoxicity).

Evaluating Patient Assessment Options

It's crucial to assess parameters that are likely to be affected by the treatment. Let's review the options:

• Complete blood count (CBC): While sometimes monitored during treatment, it's not the primary *baseline* test specifically required due to the known hepatotoxicity of TB drugs.
• Liver function test (LFT): This is essential. A baseline LFT establishes the patient's liver health before starting potentially hepatotoxic medications, allowing for comparison and early detection of drug-induced liver injury.
• Lipid profile: This test measures cholesterol and triglycerides. It is not a standard baseline requirement for initiating anti-tubercular therapy.
• Pulmonary function test (PFT): PFTs assess lung capacity and function. While important for managing tuberculosis itself, they are not the primary *baseline* test needed before starting the medications to monitor for drug toxicity.

Therefore, a baseline Liver function test is the most critical assessment among the choices provided when initiating anti-tubercular treatment.